Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | CALML3 | P27482 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SDHA | P31040 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998938 | 1.00 | MAOA (0.46) | MAOAGRM2MAOBCALML3LMNA | |
| SCHEMBL5504830 | 0.89 | MAOA (0.56) | MAOAGRM2MAOBCALML3LMNA | |
| SCHEMBL5504839 | 0.89 | MAOA (0.56) | MAOAGRM2MAOBCALML3LMNA | |
| SCHEMBL5999012 | 0.87 | MAOA (0.50) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL5999288 | 0.83 | GRM2 (0.39) | MAOAGRM2MAOBCALML3LMNA | |
| SCHEMBL5517629 | 0.83 | GRM2 (0.39) | MAOAGRM2MAOBCALML3LMNA | |
| SCHEMBL5001291 | 0.83 | MAOA (0.44) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL5001289 | 0.83 | MAOA (0.44) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL5998404 | 0.82 | MAOA (0.47) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL3046132 | 0.81 | MAOA (0.48) | MAOAMAOBCALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | LUEHR GARY W | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | OXA1L, OXSR1, OXER1 | MAOA 766/4885GRM2 3345/4885MAOB 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.